Mumbai, November 12, 2026: Indo Borax and Chemicals Ltd, one of India's leading manufacturers of boron-based chemicals, posted 16.0% growth in consolidated operating income for H1FY27 to Rs. 129.29 crore, up from Rs. 111.42 crore in H1FY26. The company’s consolidated Profit After Tax for H1FY27 stood at Rs. 21.00 crore, compared to Rs. 26.47 crore. The company’s Adjusted EBITDA and PAT margins (both on a consolidated basis) for H1FY27 stood at 21.7% and 15.4%, respectively.
|
Consolidated Financial Highlights (Rs. Crore) |
||||||
|
Particulars |
Q2 FY27 |
Q2 FY26 |
Growth (%) |
H1 FY27 |
H1 FY26 |
Growth (%) |
|
Operating Income |
58.94 |
57.85 |
1.9 |
129.29 |
111.42 |
16 |
|
Total Income |
63.35 |
61.42 |
3.1 |
136.26 |
118.01 |
15.5 |
|
EBITDA |
1.48 |
10.5 |
(-85.9) |
21.28 |
22.71 |
(-6.3) |
|
EBITDA Margin (%) |
2.5 |
18.2 |
|
16.5 |
20.4 |
|
|
*Adjusted EBITDA |
7.93 |
10.58 |
(-25.0) |
28.09 |
22.85 |
22.9 |
|
*Adjusted EBITDA Margin (%) |
13.5 |
18.3 |
|
21.7 |
20.5 |
|
|
PAT |
4.75 |
16.26 |
(-70.8) |
21 |
26.47 |
(-20.7) |
|
PAT Margin (%) |
7.5 |
26.5 |
|
15.4 |
22.4 |
|
|
EPS (Rs.) |
1.47 |
5.07 |
(-71.0) |
6.54 |
8.25 |
(-20.7) |
|
* Adjusted EBITDA = EBITDA (+) ESOP expense (+) Forex gain |
||||||
For Q2FY27, the company’s Consolidated Operating income stood at Rs 58.94 crore, compared to Rs 57.85 crore in Q2FY26. Consolidated EBITDA for Q2 FY27 stood at Rs 7.93 crore, while PAT stood at Rs 4.75 crore. EBITDA margin came under pressure due to high raw material costs in the quarter, driven by global supply chain challenges. The company’s PAT margins of Q2 FY27 ,were net of expenses of Rs 6.64 crore, related to the acquisition of Kronox Lab Sciences Ltd as a subsidiary.
Commenting on the company’s performance during the quarter, Mr. Suresh Kalra, Managing Director & CEO, Indo Borax, said, “The quarter under review witnessed steady demand across our key product segments, despite the seasonal impact of the monsoon. However, profitability remained under pressure due to higher raw material costs and geopolitical uncertainties in the Middle East, thereby impacting the overall cost environment. We will continue to focus on operational efficiencies, prudent cost management and optimising product mix to navigate these challenges in the coming quarters.
“The quarter under review also witnessed strategic integration and stabilisation of synergies with the recently acquired Kronox Lab Sciences, in terms of markets of distribution and procurement ecosystem. Going forward, we are confident of sustaining the growth momentum and strengthening our margins further, backed by diversification, premiumisation and disciplined execution”, further added Mr. Kalra.
The company has also recently received Board approval to amalgamate its wholly owned subsidiary, Indoborax Infrastructure Private Ltd, with Indo Borax Chemicals. This will be subject to necessary approvals from NCLT and other regulatory authorities.
“We expect the proposed amalgamation to unlock greater operational efficiencies by enabling the pooling and optimal utilisation of resources across the combined entity. It will also facilitate sharper management focus, simplify governance structures and enable more agile decision-making, thereby creating a more integrated and efficient organisation,” Mr. Kalra said.
